소장자료

>>
소장자료
>
000 cam i
001 2210080851724
003 OCoLC
005 20190103135216
006 m d
007 cr un|||||||||
008 160902s2016 dcua ob 100 0 eng
016 a1016921522DNLM
019 a953631429a953662089a953922171
020 a9780309438841
020 a0309438845
020 a9780309438858
020 a0309438853
035 a1284486b(NT)
035 a(OCoLC)953532375z(OCoLC)953631429z(OCoLC)953662089z(OCoLC)953922171
040 aNLMbengerdacNLMdSCBdEBLCPdYDXCPdCUSdNdMMUdIDBd221008
042 apcc
050 aRM301.25
060 a2017 A-054
060 aQV 745
072 aMEDx0710002bisacsh
082 a615
100 aBoname, Morgan L.,eauthor.
245 00 aAdvancing the discipline of regulatory science for medical product development :ban update on progress and a forward-looking agenda : workshop summary /cMorgan L. Boname, Amanda Wagner Gee, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine.
260 aWashington, DC :bNational Academies Press,c[2016]
300 a1 online resource (1 PDF file (xvi, 87 pages)) :billustrations.
336 atextbtxt2rdacontent
337 acomputerbc2rdamedia
338 aonline resourcebcr2rdacarrier
504 aIncludes bibliographical references.
505 aIntroduction -- Characterizing the Implementation science landscape -- Regulatory science applications: using case studies to focus on approaches to advance the discipline -- Regulatory science infrastructure and workforce -- Challenges and opportunities in regulatory science -- Appendix A: Bibliography -- Appendix B: Workshop agenda -- Appendix C: Participant biographies.
520 aThe field of endeavors known as "regulatory science" has grown out of the need to link and integrate knowledge within and among basic science research, clinical research, clinical medicine, and other specific scientific disciplines whose focus, aggregation, and ultimate implementation could inform biomedical product development and regulatory decision making. Substantial efforts have been devoted to defining regulatory science and communicating its value and role across the scientific and regulatory ecosystems. Investments are also being made in technology infrastructure, regulatory systems, and workforce development to support and advance this burgeoning discipline. In October 2015, the National Academies of Sciences, Engineering, and Medicine held a public workshop to facilitate dialogue among stakeholders about the current state and scope of regulatory science, opportunities to address barriers to the discipline's success, and avenues for fostering collaboration across sectors. Participants explored key needs for strengthening the discipline of regulatory science, including considering what are the core components of regulatory science infrastructure to foster innovation in medical product development. This report summarizes the presentations and discussions from the workshop.
536 aThis activity was supported by AbbVie, Inc.; the American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly & Co.; FasterCures; Friends of Cancer Research; GlaxoSmithKline (Contract No. 005319); Johnson & Johnson; Merck & Co., Inc. (Contract No. CMO-141224-000649); National Institutes of Health (NIH) (Contract No. HHSN263201200074I; Task Order HHSN26300023): National Cancer Institute (NIH), National Center for Advancing Translational Sciences (NIH), National Institute of Allergy and Infectious Diseases (NIH), National Institute of Mental Health (NIH), and National Institute of Neurological Disorders and Stroke (NIH); New England Journal of Medicine; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals (Contract No. 53108); and U.S. Food and Drug Administration (Contract No. 1R13FD005496-01). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
588 aDescription based on online resource; title from PDF title page (viewed on October 31, 2016)
590 aMaster record variable field(s) change: 082
610 aUnited States.bFood and Drug Administration.
650 aDrug Discovery
650 aGovernment Regulation
650 aDrug and Narcotic Control
650 aConsumer Product Safety
650 aEquipment and Supplies
650 aTherapies, Investigational
650 aDrug developmentxTechnological innovationszUnited States.
650 aResearch.
650 aPharmaceutical policyzUnited States.
650 aMEDICAL / Pharmacology2bisacsh
651 aUnited States
655 aCongresses
655 aElectronic books.
700 aGee, Amanda Wagner,eauthor.
700 aClaiborne, Anne B.,eauthor.
710 aNational Academies of Sciences, Engineering, and Medicine (U.S.).bForum on Drug Discovery, Development, and Translation,eissuing body.
711 aAdvancing the Discipline of Regulatory Science for Medical Product Development: an Update on Progress and a Forward-Looking Agenda (Workshop)d(2015 :cWashington, D.C.)
776 iPrint version:tAdvancing the discipline of regulatory science for medical product development.dWashington, DC : the National Academies Press, [2016]z0309438845w(OCoLC)953843252
856 3EBSCOhostuhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1284486
938 aEBL - Ebook LibrarybEBLBnEBL4591892
938 aYBP Library ServicesbYANKn13074154
938 aEBSCOhostbEBSCn1284486
994 a92bN
Advancing the discipline of regulatory science for medical product development :an update on progress and a forward-looking agenda : workshop summary /Morgan L. Boname, Amanda Wagner Gee, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine
종류
전자책
서명
Advancing the discipline of regulatory science for medical product development :an update on progress and a forward-looking agenda : workshop summary /Morgan L. Boname, Amanda Wagner Gee, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine
저자명
발행사항
Washington, DC : National Academies Press [2016]
형태사항
1 online resource (1 PDF file (xvi, 87 pages)) : illustrations.
주기사항
Includes bibliographical references. / The field of endeavors known as "regulatory science" has grown out of the need to link and integrate knowledge within and among basic science research, clinical research, clinical medicine, and other specific scientific disciplines whose focus, aggregation, and ultimate implementation could inform biomedical product development and regulatory decision making. Substantial efforts have been devoted to defining regulatory science and communicating its value and role across the scientific and regulatory ecosystems. Investments are also being made in technology infrastructure, regulatory systems, and workforce development to support and advance this burgeoning discipline. In October 2015, the National Academies of Sciences, Engineering, and Medicine held a public workshop to facilitate dialogue among stakeholders about the current state and scope of regulatory science, opportunities to address barriers to the discipline's success, and avenues for fostering collaboration across sectors. Participants explored key needs for strengthening the discipline of regulatory science, including considering what are the core components of regulatory science infrastructure to foster innovation in medical product development. This report summarizes the presentations and discussions from the workshop.
관련 URL

소장정보

도서예약
서가부재도서 신고
보존서고신청
캠퍼스대출
우선정리신청
검색지인쇄
등록번호 청구기호 별치기호 소장위치 대출상태 반납예정일 서비스
전자자료는 소장사항이 존재하지 않습니다

책소개

전체 메뉴 보기